Use of Cytochrome P450 Enzymes
Patients taking Candeur with other compounds metabolized by CYP2C9 and CYP3A4 enzymes are at an increased risk. Patients should be carefully monitored and caution should be exercised
when using these combinations.
Use of Terfenadine
Patients taking Candeur with terfenadine are at an increased risk. Such patients may experience abnormal heart rhythm disorder (QT prolongation). The use of Candeur at a dose lower than 400 mg per day with terfenadine should be monitored carefully.
Use of Halofantrine
Patients taking Candeur with halofantrine are at an increased risk. Such patients may experience prolonged and irregular heartbeat. Candeur and halofantrine should not be used together.
Patients with a disturbance in the functioning of the kidney are at an increased risk. Candeur should be given with caution to patients who have kidney problems.
Patients with low potassium
level and heart failure are at an increased risk when using this medicine. Such patients are at risk of life-threatening heart disorders causing rhythm problems of the heart. Candeur should be taken with caution in patients of heart rhythm disorders.
Abnormal Functioning of Kidney Glands
Patients on treatment with Candeur may experience adrenal insufficiency.
Women in their first Trimester of Pregnancy
The use of this medicine in a high dose in women who are in their first trimester are at an increased risk of having birth defects in their baby. The children from these women may have short head (brachycephaly), abnormal facies, abnormal skull development, splits in the upper lip and the roof of the mouth (cleft palate), bent leg bone (femoral bowing), thin ribs and long bones, curving of joints (arthrogryposis), and heart disease related to birth. The pregnant women should be informed of the potential hazard to the child.
Patients with serious disorders such as AIDS
are at an increased risk. These patients may develop serious skin rashes
when using this medicine. Closely monitor the patients who develop rashes and the medicine should be discontinued in case of symptoms further progress.
Severe Allergic Reaction (Anaphylaxis)
The patients with anaphylaxis
are at an increased risk when using this medicine. This medicine should be discontinued if the patient experiences a severe allergic reaction.
Patients with abnormal liver function are at an increased risk when using this medicine. These patients may have a fatal liver damage. Monitoring should be required for the development of more severe liver injuries. This medicine should be discontinued if the signs and symptoms consistently develop with the use of Candeur.
Intolerance to Sugars
Patients with a family history of galactose intolerance and defect in glucose-galactose absorption are at an increased risk. Such patients should not be advised to take Candeur capsules containing lactose.